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Short title: oral hygiene in patients with DG. 
Summary 
The aim of this prospective pilot study was to evaluate the efficiency of an oral 
hygiene protocol, in combination with a solution of sodium iodide associated to 
salicylic acid (SISA), in patients affected by desquamative gingivitis (DG). Patients 
not totally responding to conventional topical therapies, were selected. They received 
oral hygiene instruction with non-surgical periodontal therapy in a 21-day cohort 
study (during 3 weekly appointments). The SISA was used at the end of each session, 
with an impregnated gauze (with 5 ml of the solution) applied for 15 minutes for the 
upper jaw, and for other 15 minutes with a novel gauze for the lower. Evaluated 
clinical outcome variables included the full mouth plaque (FMPS) and bleeding 
(FMBS) scores, probing depth, patient related outcome and clinical gingival signs. A 
total of 20 patients were recruited. Two months after concluding the planned protocol, 
a statistical significant reduction was observed for FMPS (P=.032), FMBS (P=.038), 
reported pain (P=.000) and gingival clinical improvement (P=.005).  
Topical application of SISA and professional oral hygiene procedures are connected 
with worthy improvement of gums status, and decrease of related pain, in subjects 
affected by severe DG. 
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Introduction 
Desquamative gingivitis (DG) neither is a specific disorder nor recognizes a single 
aetiopathogenesis; it simply represents the gingival manifestation associated with 
some heterogeneous mucocutaneous disorders (e.g. oral lichen planus, mucous 
membrane pemphigoid, pemphigus vulgaris and few others); epithelial desquamation, 
erythema and erosive and/or vesiculo-bullous lesions usually characterize it (1-5). DG 
has no association with loss of attachment and alveolar bone destruction; nonetheless, 
it can significantly compromise the patient’s approach to proper oral hygiene and this 
could denote a possible risk factor for long-standing periodontal health (6-9). There 
have been limited studies regarding therapy for DG (6). We recently demonstrated 
that detailed oral hygiene procedures and proper non-surgical periodontal therapy 
could be associated with improvement of clinical and patient-related outcomes in 
distinctive cases (10-12). 
The “Fertomcidina-U”® is a novel formulation, realized as a salsobromoiodic solution 
containing salicylic acid and magnesium bisphosphate, having a strong bactericide 
and fungicide action, applicable on human skin and mucosae for tissues reparation 
and re-epithelization (13,14). Because of its action, which is related to the sodium-
iodide that in the presence of oxygen acts as iodophor, developing small amounts of 
iodine, this medication should be contraindicated in patients with thyroid disorders. 
 The aim of this study was to evaluate the clinical efficiency of an oral hygiene 
protocol, in combination with a solution of sodium iodide associated to salicylic acid, 
in patients affected by DG not completely responding to conventional topical 
therapies. 
 
Materials and Methods 
Subjects with histologically proven DG [oral lichen planus (OLP), plasma cell 
gingivitis (PCG), mucous membrane pemphigoid (MMP) and pemphigus vulgaris 
(PV)] were selected among individuals regularly followed at the Oral Medicine Unit 
of the CIR – Dental School of the University of Turin, Italy, between January 2012 
and September 2015.  
Patients were treated topically (and also systemically in cases with a diagnosis of PV) 
in the preceding 12 months. 
Exclusion criteria included: (i) history of periodontal therapy (surgical and non-
surgical) in the previous 6 months; (ii) less than 18 teeth, (iii) pregnancy and (iv) 
diabetes mellitus.  
All eligible candidates for this study were informed about the experimental protocol, 
and signed a consent form. The ethics review board of the CIR - Dental School 
approved the study (prot. N° II-pato-2011CD).   
A prospective case series protocol was designed. Patients received a complete 
periodontal examination at baseline visit, including full mouth plaque scores (FMPS), 
full mouth bleeding upon probing scores (FMBS) and probing pocket depth (PPD). 
Activity scores [modified from Escudier and co-workers (15)], including extent and 
severity of the gingival lesion (site score), were documented as previously reported 
(10). Score ranged from 1 to 12, with higher results indicating a worse clinical aspect. 
Patient related outcomes included pain perception assessed at each visit by Visual 
Analogue Scale (VAS). The VAS consisted of a 10 cm-horizontal line marked with 0 
(=no pain) to 10 (=most severe pain experienced). Total resolution of all clinical 
symptoms was defined as the absence of any discomfort, corresponding to a zero 
VAS score. Partial response, worsening, or persistence of the patient’s condition 
meant a decrease, increase, or no change at all in the patient’s score respectively.  
An experienced dental hygienist provided thorough supra- and sub-gingival scaling 
within 3 weeks (once weekly). During each visit, subjects were instructed about 
proper oral hygiene maintenance at home; such instructions were reinforced at each 
visit and were personalised when necessary. The “Fertomcidina-U”® (Theriaca S.r.l., 
Rome, Italy) was used at the end of each of the 3 sessions performed: a gauze 
impregnated with 5 ml of the solution was applied for 15 minutes for the upper jaw 
and for other 15 minutes for the lower using another new gauze impregnated. Patients 
were advised not to swallow the medication, and to avoid eating and drinking for at 
least 3 hours after the treatment. 
The technical procedures provided in the protocol are fully detailed in Table I. 
Comparative statistics were performed between T0 and T5. Paired samples test was 
used to test the difference in FMBS, FMPS and PPD. Wilcoxon’s signed rank was 
used to calculate the significance of the patient related outcomes (VAS) and in 
clinical outcome (activity score). P-values £ .05 were considered to be statistically 
significant. SPSS (SPSS for windows, version 11, SPSS inc, Chicago, IL, USA) 
statistical software was utilized. 
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Results 
Twenty patients were included: 9 had OLP, 6 had PV, 4 had GPC and 1 had MMP. 
The mean age at baseline was 56.95 (±16.75) years.  Three were male (15%).  
Table II reports the comparison of selected data during the protocol period. A 
reduction in FMBS (P=.032) and FMPS (P=.038) were observed. Moreover, a 
statistical significant reduction in symptoms reported was observed with a reduction 
in VAS scores (P=.000). Also interestingly, the clinical gingival involvement 
improved after the proposed therapy (P=.005).  
All subjects were initially advised of the possible unpleasant taste of the medication, 
and 60% of them still reported this problem at the end of the follow-up period, but 
none of them were not able to complete the treatment. No patient complained of other 
adverse effects. 
 
Discussion 
This is the first prospective case series of DG patients treated with a solution of 
sodium iodide associated to salicylic acid in combination with non-surgical 
periodontal therapy. This initial pilot analysis suggested that the proposed protocol 
could be a possible mean for reducing clinical gingival inflammation and improve 
patient related outcomes in patients with different forms of DG. 
It has been reported that several systemic diseases, affecting the gingiva, could have 
an inflammatory profile composed of two main reasons: one may be a non-specific 
inflammatory response to plaque (thus a plaque-induced inflammation); another 
response may be due to a specific disease or agent, today not well understood (5,6).  
No concluding standard of care has been set for DG and there is no prospective 
literature on long-term management of these subjects (4). The present report was 
developed by taking motivation from conclusions achieved by earlier works reporting 
that patients affected by different DG conditions, and treated with non-surgical 
periodontal therapy, are connected with improvement of gingival status and decrease 
in gingival-related pain (10-12). However, plaque removal alone cannot induce severe 
DG regression. That’s why we decided to add “Fertomcidina-U”® topically to 
accelerate the healing process. In fact, it has been reported that the salicylic acid acts 
by environment acidification, with different anti-inflammatory assets, sometimes 
comparable to corticosteroids (16). The keratoplastic properties are showed by studies 
reporting both an increased thickness of epithelial tissues and mitotic index of the 
basal layer (17,18). This is the rationale to use this compound in treating epithelial 
inflammatory diseases. Moreover, this medication could be used to treat dissimilar 
kind of oral pathogens, not only the typical periodontal ones but also others quite 
different, normally resident in the oral cavity as well as introduced in other ways (19, 
20). 
Non-surgical periodontal therapy is the most common therapeutic procedure for 
patients with periodontal diseases, eliminating or reducing the microbial counts of 
subgingival flora following improvements in clinical parameters and oral health of 
patients (21). And it is now clear that the previous statement is effective also for DG. 
Oral hygiene improved in all participants. This is bound to the time devoted to oral 
hygiene enactment and home directives. Patients were favourably motivated to 
perform their routinely home maintenance, and their cooperation was above all 
indispensable. 
The positive clinical results obtained with appropriate professional oral hygiene could 
serve as a basis of recommending this as complementary line therapeutic intervention, 
especially in patients with pure gingival involvement, in order to decrease gingival 
inflammation and related pain and help affected patients in maintaining a good oral 
hygiene. And the simple use of a topically applied solution of sodium iodide 
associated to salicylic acid could improve the healing progression, without adverse 
effects. However, it is chief to remember that the main limitations are the lack of a 
control group, and that there were no intra-reliability analysis of the examiner and no 
blinding included in the design. For these motivations, additional randomized trials, 
with different approaches and larger sample size, are however needed. 
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Table I. Clinical protocol used. 
 
Time 0 (T0): 
- Oral evaluation and comprehensive measurements* 
Time 1_Day 7 (T1): 
- Scaling and root planning 
- “Fertomcidina-U” topical application 
- Oral hygiene instruction:  
   a) use a ultra-soft toothbrush1 for manual brushes, placing the  bristles at a 45° angle to the 
tooth surface at the gum edge and then move the bristles back and forth in short (tooth-wide) 
strokes or small circular movements 
Time 2_Day 14 (T2): 
- Scaling and root planing  
- “Fertomcidina-U” topical application 
Time 3_Day 21 (T3): 
- Scaling and root planing  
- “Fertomcidina-U” topical application 
- Oral hygiene instruction:  
   a) use a super-soft toothbrush2 for manual brushes, placing the  bristles at a 45° angle to 
the tooth surface at the gum edge and then move the bristles back and forth in short (tooth-
wide) strokes or small circular movements 
Time 4_Day 49 (T4_1 month after finishing the proposed protocol): 
- Oral hygiene instruction:  
   a) use a soft toothbrush3 for manual brushes, placing the  bristles at a 45° angle to the tooth 
surface at the gum edge and then move the bristles back and forth in short (tooth-wide) 
strokes or small circular movements 
- Oral evaluation; VAS measurement and activity score 
Time 5_Day 77 (T5_2 months after finishing the proposed protocol): 
- Oral evaluation and comprehensive measurements* 
 
* Comprehensive measurements include: 
- VAS (visual analogue scale), a chromatic scale graduated from 0 (no pain) to 10 (unbearable pain), where it defines intensity of 
pain strong or very strong. 
- FMBS (full mouth bleeding score). 
- FMPS (full mouth plaque score). 
- PPD (probing pocket depth). 
- Activity Score: to value the extent and severity of the gingival lesion. 
 
 
 
 
1Curaprox CS 5460  
2Curaprox CS 3960 
3Curaprox CS 1560 
 
Table II. The comparison of selected data at time 0 (T0), and at one (T4) or two 
(T5) months after the proposed protocol. 
 
 T0 T4 T5 p* 
Full mouth bleeding score (%) 59.00 ± 16.25 - 23.88 ± 11.11 .032 
Full mouth plaque score (%) 45.02 ± 13.63 - 29.20 ± 2.73 .038 
Probing depth (mm) 2.48 ± 0.51 - 2.29 ± 0.67 .791 
Referred symptoms (VAS score) 5 ± 1.32 3.38 ± 1.19 2.44 ± 1.42 .000 
Activity score 6.48 ± 1.20 3.08 ± 1.77 2.81 ± 1.79 .005 
 
*Comparative statistics were performed between T0 and T5. Paired samples test was used to test the difference in FMBS, FMPS 
and PPD. Wilcoxon’s signed rank was used to calculate the significance of the patient related outcomes  and in gingival clinical 
outcome (activity score). 
 
 
 
 
